Kate Anderton

652 total citations
8 papers, 193 citations indexed

About

Kate Anderton is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kate Anderton has authored 8 papers receiving a total of 193 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kate Anderton's work include Peptidase Inhibition and Analysis (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Kate Anderton is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Kate Anderton collaborates with scholars based in United Kingdom, United States and Australia. Kate Anderton's co-authors include Elizabeth Garrett‐Mayer, Melanie B. Thomas, Charles D. Smith, Yan Zhuang, Besim Öğretmen, Carolyn D. Britten, Lynn W. Maines, Keisuke Shirai, Vinay Duddalwar and Munazza Anis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Kate Anderton

6 papers receiving 186 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kate Anderton United Kingdom 4 119 37 36 34 32 8 193
Emilie Le Roux France 5 151 1.3× 35 0.9× 34 0.9× 15 0.4× 31 1.0× 5 205
Er‐Bin Zhang China 8 188 1.6× 40 1.1× 53 1.5× 22 0.6× 26 0.8× 8 282
Isabel Weinhäuser Brazil 5 110 0.9× 21 0.6× 49 1.4× 11 0.3× 18 0.6× 19 217
Linling Ju China 11 208 1.7× 22 0.6× 45 1.3× 22 0.6× 47 1.5× 41 314
María Elena Elez Spain 6 50 0.4× 37 1.0× 115 3.2× 13 0.4× 19 0.6× 10 167
Wei Chu China 7 53 0.4× 31 0.8× 95 2.6× 9 0.3× 35 1.1× 9 179
Itaru Nishizuka Japan 5 90 0.8× 33 0.9× 61 1.7× 11 0.3× 20 0.6× 7 199
Diptee Kulkarni United States 10 192 1.6× 27 0.7× 103 2.9× 15 0.4× 21 0.7× 13 304
Lejie Cao China 10 190 1.6× 13 0.4× 161 4.5× 15 0.4× 19 0.6× 17 372
Xiaoguang Liu China 10 114 1.0× 30 0.8× 81 2.3× 10 0.3× 38 1.2× 17 229

Countries citing papers authored by Kate Anderton

Since Specialization
Citations

This map shows the geographic impact of Kate Anderton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Anderton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Anderton more than expected).

Fields of papers citing papers by Kate Anderton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Anderton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Anderton. The network helps show where Kate Anderton may publish in the future.

Co-authorship network of co-authors of Kate Anderton

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Anderton. A scholar is included among the top collaborators of Kate Anderton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Anderton. Kate Anderton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
2.
Leishman, Andrew J., Asolina Braun, Mitul Patel, et al.. (2022). 1131 GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses. Regular and Young Investigator Award Abstracts. A1175–A1175. 2 indexed citations
3.
4.
Quibell, Martin, Carmen H. Tong, Kristopher Clark, et al.. (2021). 553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition. SHILAP Revista de lepidopterología. A583–A583. 3 indexed citations
5.
Costa, Luciano J., Heather Landau, Saurabh Chhabra, et al.. (2018). Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation. 24(7). 1379–1385. 15 indexed citations
6.
7.
Britten, Carolyn D., Elizabeth Garrett‐Mayer, Keisuke Shirai, et al.. (2017). A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 23(16). 4642–4650. 130 indexed citations
8.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emilie Le Roux Breakdown of academic impact, for papers by Er‐Bin Zhang Breakdown of academic impact, for papers by Isabel Weinhäuser Breakdown of academic impact, for papers by Linling Ju Breakdown of academic impact, for papers by María Elena Elez Breakdown of academic impact, for papers by Wei Chu Breakdown of academic impact, for papers by Itaru Nishizuka Breakdown of academic impact, for papers by Diptee Kulkarni Breakdown of academic impact, for papers by Lejie Cao Breakdown of academic impact, for papers by Xiaoguang Liu
Rankless by CCL
2026